Speaker Profile
MD, MBA, MSc, Medical Director, Biological Dynamics
Biography
Dr. Harmeet Dhani is lead Medical Director at Biological Dynamics, an innovative liquid biopsy biotechnology company that uses extracellular vesicle (EV)-based protein biomarkers for early cancer detection, and neurodegenerative and infectious diseases.Harmeet is a surgeon scientist who after completing his medical degree, went onto general surgery residency and pursued transplant and hepato-pancreato-biliary surgery, including a research fellowship at Georgetown University where he has an accomplished track record in studying liver, intestinal disease and transplantation. Most notably, he has published and received awards for his work to elucidate markers of allograft rejection, including Emerging Livers Scholar Award from the American Association for the Study of Liver Disease and the Young Investigator Award from American Transplant Congress.He continued to decorate his career with experience in the oncology division at Natera. He also holds a Master’s in Clinical Research from UCSD, and is currently earning his MBA part-time at Georgetown University.
Talk
Never too late – championing earlier cancer detection
Changing the paradigm of early cancer detection through a novel exosome-based platform called VeritaTM. BioDyn empowers at-risk patients and providers with a highly sensitive biomarker assay for clinical adoption in multi-cancers, one cancer at a time.
Session Abstract – PMWC 2023 Silicon Valley
Track Chair: Cindy Perettie, Roche
- PMWC 2023 Award Ceremony
- Luis Alberto Diaz Jr., MSK
- Razelle Kurzrock, Medical College of Wisconsin - Non-invasive Liquid Biopsy Techniques (PANEL)
Chair: Razelle Kurzrock, Medical College of Wisconsin
- Apostolia Tsimberidou, MD Anderson
- Mandana Kamgar, MD Medical College of Wisconsin
- Mina Nikanjam, UCSD
- Ash Alizadeh, Stanford University - Liquid Biopsy Challenges and Limitations (PANEL)
Chair: Victor Lin, Mary Bird Perkins
- Luis Alberto Diaz Jr., MSK
- Maximilian Diehn, Stanford
- Dana Dilbeck, Agilent
- Emma Shtivelman, Cancer Commons - Liquid Biopsy in Clinical Trials: Learnings and COVID Experience (PANEL)
Chair: Cindy Perettie, Roche Diagnostics
- Eric Peters, Genenetch
- Andrew Mckenzie, Sarah Cannon
- Yang Pan, Gilead
- Alan Sandler, Mirati Therapeutics - Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing
Chair: Tom Beer, Exact Sceinces
- Liquid Biopsy for Early Cancer Detection (PANEL)
Chair: Priti Hegde, Foundation Medicine
- Daniel Kim, UCSC
- Mike Nolan, Freenome
- Jeffrey Venstrom, Grail Bio
- Kathryn Phillips, UCSF
- Lon Castle, eviCore healthcare
- Tom Beer, Exact Sciences - Liquid Biopsy for Minimal Residual Disease (PANEL)
Chair: Minetta Liu, Natera
- Peter Bach, Delfi diagnostics
- Laura Vantveer, UCSF
- Susan Bobulsky, Adaptive
- Joshua Cohen, Johns Hopkins
- PMWC Showcase
- Harmeet Dhani, Biological Dynamics
- Varsha Rao, Claret Bio - PMWC NCI Showcase
- Xianghong Jasmine Zhou, EarlyDiagnostics
